Navigation Links
Xenon Announces Appointment of VP, Discovery Research
Date:2/6/2008

VANCOUVER, Canada, Feb. 6 /PRNewswire/ -- Xenon Pharmaceuticals Inc., a drug discovery and development company, is pleased to announce today that it has appointed Charles J. Cohen as Vice President, Discovery Research.

"We are delighted to welcome Charlie to the Xenon team," commented Simon Pimstone, Xenon's President and CEO. "Charlie brings a unique combination of drug discovery experience and leadership including in areas that are highly relevant to Xenon such as pain. With a drug candidate for pain currently in clinical trials, and a backup compound expected to follow, we are certain that Charlie's background will be of great benefit to Xenon. In addition to his experience in the pain area, Charlie brings broad and diverse expertise which will be applicable to our multiple discovery and pre-clinical programs."

Dr. Cohen has spent the past approximately 25 years in the pharmaceutical/biotechnology industry with positions at Bayer Pharmaceuticals, Merck & Co and Vertex Pharmaceuticals. He held senior scientific positions and has published widely in the area of pain and more broadly in cellular neuroscience and neurology. Dr. Cohen received his PhD in Biophysics and Theoretical Biology from the University of Chicago.

About Xenon Pharmaceuticals Inc.

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies focusing in the areas of Pain, Diabetes/Obesity, Anemia and Iron Overload. Xenon has partnerships with Novartis Pharma AG, Roche and Takeda Pharmaceutical Company Ltd. For more information, visit the Company's website at http://www.xenon-pharma.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.


'/>"/>
SOURCE Xenon Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
2. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
3. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
4. DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
5. Physicians Reference Laboratory Announces New Diagnostic for Womens Health
6. CardioTech Announces Conference Call on February 12 at 2:30 PM Eastern for Third Quarter of Fiscal 2008
7. NeoStem Announces NY State License for Adult Stem Cell Collection
8. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
9. China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results
10. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
11. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2017)... ... June 15, 2017 , ... angelMD ... medical device startup. Dan Parsley, angelMD’s SVP of Corporate Development, served as the ... angelMD syndicate is part of Saranas’ recently announced $4 million Series B financing ...
(Date:6/15/2017)... ... June 15, 2017 , ... Adam Equipment, a ... to assemble a lab workstation. The guide outlines the procedure in four simple ... Eclipse balance, AVT anti-vibration table, OIML/ASTM certified weights, and Adam DU specialized software. ...
(Date:6/14/2017)... ... June 14, 2017 , ... The ... Sciences (TCELS) announces that they’re co-hosting a delegation from Thailand at BIO 2017 ... largest biotech industry gathering in the world, regroups more than 1,100 biotech companies, ...
(Date:6/14/2017)... NJ, USA – , ... ... (PRWEB) June 14, 2017 -- Diagenode, a leading global ... research, has licensed a new technology specific for ChIP-sequencing ... Chromatin immunoprecipitation followed by sequencing (ChIP-seq) allows the study ...
Breaking Biology Technology:
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
Breaking Biology News(10 mins):